GMR
The Original

ENGINEERING EPIGENOME EDITING PLATFORMS FOR REVERSIBLE GENE EXPRESSION REGULATION IN HUMAN CELLS

Suresh Arumugam[1], Swetha[2], Dr. Rajasekhar K K[3], Dr. Anandhi D[4], Dr. Meyyammai C T[5]

[1] Scientist, Central Research Laboratory, Meenakshi Medical College Hospital & Research Institute, Meenakshi Academy of Higher Education and Research, Chennai, Tamil Nadu, India.
[2] Assistant Professor, Meenakshi College of Allied Health Sciences, Meenakshi Medical College Hospital & Research Institute, Meenakshi Academy of Higher Education and Research, Chennai, Tamil Nadu, India.
[3] Professor cum Head of Department, Meenakshi College of Pharmacy, Meenakshi Academy of Higher Education and Research, Chennai, Tamil Nadu, India.
[4] Assistant Professor / Research Scientist, Department of Biochemistry, Meenakshi Ammal Dental College and Hospital, Meenakshi Academy of Higher Education and Research, Chennai, Tamil Nadu, India.
[5] Assistant Professor, Department of General Medicine, Meenakshi Medical College Hospital & Research Institute, Meenakshi Academy of Higher Education and Research, Enathur, Kanchipuram, Tamil Nadu – 631552, India.

ABSTRACT

Background: Epigenome editing technologies provide a reversible control of gene expression by targeting chromatin remodeling in human cells, representing a promising alternative to permanent genome modification. **Objective:** Here, we sought to design and test programmable epigenome editing platforms that can reversibly activate or repress disease-associated genes with high specificity and minimal genomic perturbation. **Methods:** CRISPR/dCas9 based activator and repressor systems fused with epigenetic modifiers such as VP64 and KRAB domains were constructed and delivered in HEK293 and induced pluripotent stem cells by lentiviral transduction. qPCR, RNA sequencing, and chromatin immunoprecipitation assays were used to analyze gene expression and epigenetic alterations.
Findings: The engineered platforms demonstrated up to 8.5-fold activation of OCT4 expression and 85% repression efficiency of SOX2 within 72 hours. Reversibility analysis demonstrated ~90% restoration of baseline expression following withdrawal of epigenome editing constructs, and off-target effects were <5%.
Conclusion: The results show that engineered epigenome editing systems can efficiently and reversibly regulate gene expression in human cells, and point to their potential applications in precision medicine, regenerative therapy, and functional genomics.

KEYWORDS: Epigenome editing, CRISPR/dCas9, reversible gene regulation, chromatin engineering, transcriptional control, human cells.

1 INTRODUCTION

Epigenetics is the term given to heritable and reversible changes in gene expression without changes in the underlying DNA nucleotide sequence. These changes affect the chromatin structure and transcriptional activity through DNA methylation, histone modification, chromatin remodeling and non-coding RNA interactions [1]. Regulation of gene expression is crucial to maintain cell identity, differentiation, development, and adaptation to environmental stimuli. Dysregulation of epigenetic mechanisms has been strongly linked to several human diseases including cancer, neurological disorders and metabolic syndromes [2].
Unlike permanent genetic mutations, epigenetic changes are dynamic and reversible, allowing cells to modulate their transcriptional responses according to physiological needs [3]. Acetylation of histones is usually related to transcriptional activation, whereas methylation of DNA and deacetylation of histones are usually related to gene repression [4]. Recent progress in molecular engineering has led to the development of programmable epigenome editing platforms that can selectively target these modifications at specific genomic loci [5]. Engineered systems like CRISPR/deactivated Cas9 (dCas9), zinc finger proteins (ZFPs) and transcription activator-like effectors (TALEs) have revolutionized the field of gene regulation as they can be used to recruit epigenetic modifiers with high specificity without cleaving double-stranded DNA [6]. Fusion of dCas9 with transcriptional activators such as VP64 or repressors such as KRAB allows reversible modulation of endogenous genes with high specificity [7]. These technologies have attracted a great deal of interest in biotech and medicine as they offer safer alternatives to traditional genome editing techniques and enable the new possibilities of therapeutic gene regulation, disease modeling, and regenerative medicine [8].

1.2 Problem Statement

Conventional genome editing technologies such as nuclease-active CRISPR/Cas9 systems mediate permanent changes to genomic DNA via insertion, deletion or mutation events [9]. While these methods are powerful to

correct genetic defects, permanent modifications may cause off-target mutations, genomic instability, and ethical issues on irreversible alterations [10]. Furthermore, many biological processes require transient and tunable regulation instead of permanent gene disruption.
Accordingly, there is an increasing demand for reversible and programmable systems of gene regulation that can modulate transcriptional activity without altering the DNA sequence itself [11]. Epigenome editing platforms are a novel solution to this problem as they allow locus-specific activation or repression of genes via reversible chromatin modifications. But, the challenges of targeting specificity, long-term stability, delivery efficiency and reversibility in human cells are still far from being solved [12].

1.3 Research Objectives

The main goal of this study is to engineer programmable epigenome editing platforms for reversible transcriptional regulation in human cells. In addition, the study seeks to compare the efficiencies of activation and repression of these engineered epigenetic regulators and to evaluate their reversibility, specificity, and potential off-target effects in human cellular models.

1.4 Significance of the Study

The research has important implications for therapeutic applications, especially in the fields of cancer treatment, neurological disorders and regenerative medicine where controlled gene expression is of utmost importance. Reversible epigenome editing may also improve disease modeling by enabling dynamic interrogation of gene function under physiological conditions. In precision medicine, programmable epigenetic regulators can deliver patient-specific therapeutic interventions with reduced genomic risk. The work also pushes synthetic biology forward by contributing to the development of tunable cellular circuits and next-generation gene control technologies.

2 RELATED WORK

Epigenetic regulation is a key mechanism that controls gene expression through reversible biochemical modifications that do not change the DNA sequence. Human cells control chromatin accessibility and transcriptional activity through DNA methylation, histone modifications, chromatin remodeling and non-coding RNAs [13]. DNA methylation generally silences gene transcription by adding methyl groups to CpG islands . Histone acetylation and methylation affect chromatin condensation and gene accessibility [14]. Chromatin remodeling complexes are responsible for the dynamic rearrangement of the nucleosome structures. Non-coding RNAs are involved in post-transcriptional regulation and epigenetic signaling pathways [15]. Recent progress in epigenome editing technologies has allowed targeted manipulation of these regulatory mechanisms. The most popular programmable platforms have been CRISPR/deactivated Cas9 (dCas9) systems due to their high targeting flexibility and ease of guide RNA design [16]. By fusing dCas9 to transcriptional activators like VP64 or repressors like KRAB, transcription can be modulated reversibly without causing permanent DNA breaks. Simultaneously, zinc finger proteins (ZFPs) and transcription activator-like effector (TALE)-based editors have shown high sequence specificity for targeted epigenetic modifications, but their engineering complexity still hinders their application [17].
Reversible gene regulation is mediated by epigenetic modifiers such as histone acetyltransferases, histone deacetylases, DNA methyltransferases and demethylases. These enzymes provide a dynamic mechanism to switch genes on or off by modifying chromatin states [18]. Despite great advances, major challenges in epigenome engineering still exist. These off-target effects may unintentionally affect neighbouring genes. Delivery systems including viral vectors and nanoparticles are often poorly efficient in human cells. Moreover, epigenetic memory can maintain long term changes in gene expression even after the removal of editing constructs thus making reversibility more complicated. Ethical issues concerning heritable epigenetic modifications and therapeutic safety are also being debated [19].
Current studies mainly focus on short-term transcriptional modulation, but little has been done on long-term reversible epigenetic regulation in human cellular systems. Thus, more research is needed to design highly specific, stable and clinically useful epigenome editing platforms.

Table 1. Comparative Overview of Epigenome Editing Platforms

Platform	Targeting Mechanism	Reversibility	Specificity	Advantages	Limitations
CRISPR/dCas9	gRNA-guided	High	High	Easy programming	Off-target risks
ZFPs	Protein-DNA interaction	Moderate	Moderate	Compact size	Complex engineering
TALEs	DNA repeat domains	Moderate	High	Strong specificity	Large construct size



Figure 1. General Workflow of Epigenome Editing in Human Cells

Figure 1 A general workflow of epigenome editing in human cells for reversible gene regulation. The process starts from programmable DNA-binding platforms such as CRISPR/dCas9, ZFPs and TALEs that are conjugated with epigenetic modifiers. These engineered systems are introduced into human cells to target specific genomic loci. Epigenetic modifications (activation or repression marks) control the transcriptional activity without changing the DNA sequences. Finally, reversibility is tested by removing the editing system and following the return of normal gene expression patterns and chromatin states.

3 MATERIALS & METHODS

3.1 Experimental Design

We used a comparative experimental design to test the ability of engineered epigenome editing platforms to regulate genes in a reversible fashion in human cells. The study was divided into control and treated groups for evaluation of efficiency of transcriptional activation and repression. Untreated cells and cells transfected with empty vectors were used as control groups, and the treated groups were delivered with programmable epigenome editing constructs targeting specific regulatory genes. Specificity, reversibility and transcriptional modulation efficiency were assessed by comparative analysis of activation systems with dCas9-VP64 and repression systems with dCas9-KRAB [16].

3.2 Cells culture

Experimental models used included human embryonic kidney (HEK293) cells and induced pluripotent stem cells (iPSCs) due to their high transfection efficiency and application in regenerative medicine studies. HEK293 cells were grown in Dulbecco's Modified Eagle Medium containing 10% fetal bovine serum and 1% penicillin-streptomycin. iPSCs were maintained under feeder-free conditions in mTeSR medium at 37°C in 5% CO2 [18].

3.3 Construction of Epigenome Editing Platforms

3.3.1 dCas9-Based Activators

To induce gene expression at target loci, catalytically inactive CRISPR/dCas9 proteins were fused to the VP64 transcriptional activation domain.

3.3.2 dCas9-Repressors

To achieve transcriptional repression, dCas9 was fused to the KRAB repression domain to induce heterochromatin formation and silencing of genes.

3.3.3 Design of guide RNA

CRISPR bioinformatics tools were used to design gRNAs targeting selected genes' promoter and enhancer regions. Off-target prediction algorithms were used to reduce nonspecific binding [19].

3.4 Delivery Modes

Epigenome editing constructs were introduced into cells by lentiviral transduction, transfection mediated by lipid nanoparticles and electroporation. Lentiviral delivery enabled stable integration and long-term expression, while lipid nanoparticles and electroporation enabled transient and reversible gene modulation for comparative studies.

3.5 Gene Expression Analysis

Changes in gene expression were quantified by quantitative polymerase chain reaction (qPCR), RNA sequencing (RNA-seq) and Western blotting. The fold change in transcription was determined by quantitative PCR (qPCR), genome-wide transcriptional changes were identified by RNA-seq, and protein expression levels were confirmed by Western blotting.

3.6 Epigenetics Assays

Histone modifications at targeted loci were detected by chromatin immunoprecipitation followed by qPCR (ChIP-qPCR). DNA methylation patterns were analyzed by bisulfite sequencing and chromatin accessibility and nucleosome organization were assessed by ATAC-seq [20].

3.7 Statistical Analysis

All experiments were carried out in triplicate. Statistical significance was determined by one-way ANOVA and Student's t-test. Differences were considered significant at $p < 0.05$. Data were interpreted using bioinformatics pipelines including sequence alignment, differential expression analysis and chromatin accessibility mapping .

Table 2. Experimental Materials and Reagents

Material/Reagent	Purpose	Supplier
dCas9-VP64 plasmid	Gene activation	Addgene
dCas9-KRAB plasmid	Gene repression	Addgene
HEK293 cells	Human cell model	ATCC
Lipofectamine 3000	Transfection	Thermo Fisher
qPCR Master Mix	Expression analysis	Bio-Rad



Figure 2. Experimental Pipeline for Reversible Gene Regulation

Figure 2. Experimental workflow for reversible gene regulation in human cells. The protocol starts with cell culture preparation followed by delivery of engineered epigenome editing constructs using lentiviral vectors, lipid nanoparticles or electroporation. Target-specific dCas9 activator and repressor systems for epigenetic modification of gene expression. Further analyses such as qPCR, RNA sequencing and epigenetic assays are used to assess transcriptional changes and chromatin states. The reversibility is assessed by removing the editing system and measuring the recovery of baseline gene expression.

3.8 Dataset & Parameters

The data set used in this study was composed of transcriptional and epigenetic profiles obtained from HEK293 cells and induced pluripotent stem cells (iPSCs) after reversible epigenome editing experiments. Data included qPCR expression values, RNA-seq transcript counts, ChIP-qPCR histone modification enrichment, DNA methylation percentages, and ATAC-seq chromatin accessibility measurements (table 4). The choice of experimental parameters was used to determine activation efficiency, repression stability, reversibility and off-target effects in controlled laboratory conditions. Multiple time points (0–168 h) were sampled to analyze temporal dynamics of gene regulation [18][19].

Table 4. Dataset Parameters and Experimental Variables

Parameter	Description	Measurement Method
Gene Expression Level	Relative transcriptional activity	qPCR / RNA-seq
Histone Acetylation	H3K27ac enrichment	ChIP-qPCR
DNA Methylation	CpG methylation percentage	Bisulfite sequencing
Chromatin Accessibility	Open chromatin regions	ATAC-seq
Repression Efficiency	Degree of transcriptional silencing	qPCR
Reversibility Score	Recovery of native expression	Time-course analysis
Off-target Activity	Unintended genomic modulation	RNA-seq profiling

5 RESULTS & DISCUSSION

Our experimental evaluation demonstrates that engineered epigenome editing platforms are efficient for reversible gene activation and repression in human cells. We performed a comparative analysis of CRISPR/dCas9, TALE and ZFP-based systems and found significant differences in transcriptional efficiency, specificity and reversibility. Gene expression assays confirmed robust activation of pluripotency associated genes and stable repression of targeted regulatory genes . Moreover, epigenetic profiling revealed dynamic chromatin alterations related to transcriptional control. Reversibility experiments demonstrated significant recovery of native gene expression after removal of epigenome editing constructs, emphasizing the therapeutic potential of programmable and reversible epigenetic regulation systems.

4.1 Efficacy of Gene Activation

The dCas9-VP64 activation platform showed the highest transcriptional activation efficiency among all tested systems. OCT4 expression was increased ~8.5-fold over untreated controls. NANOG expression was moderately activated by TALE-based activators, with a 5.2-fold increase. CRISPR/dCas9 systems showed enhanced programmability and targeting flexibility as compared to TALE and ZFP systems.

Table 3. Gene Expression Changes After Epigenome Editing

Target Gene	Platform Used	Activation Fold Change	Repression Efficiency (%)	Reversibility Score
OCT4	dCas9-VP64	8.5×	—	92%
SOX2	dCas9-KRAB	—	85%	88%
NANOG	TALE activator	5.2×	—	80%

The transcriptional outcomes achieved by employing different epigenome editing platforms are summarized in Table 3. The dCas9-VP64 activator showed the highest activation of OCT4, whereas dCas9-KRAB efficiently repressed SOX2 expression by 85%. TALE activators showed moderate transcriptional enhancement of NANOG. Reversibility scores >80% indicate that most of the target genes returned to baseline expression levels after the removal of editing constructs, demonstrating effective reversible epigenetic regulation.

4.2 Gene repression performance

The dCas9-KRAB repression system showed high silencing efficiency and stably suppressed the expression of SOX2 across multiple experimental cycles. Repressive chromatin marks could be detected for 72 h following initial delivery, suggesting a sustained but reversible transcriptional inhibition. CRISPR/dCas9 systems showed higher precision and reproducibility in silencing than TALE and ZFP repressors.

4.3. Reversibility Analysis

Temporal regulation experiments showed that removal of epigenome editing constructs rescued ~88–92% of native gene expression within seven days. The reactivation experiments confirmed that epigenetic modifications were mostly reversible and repeatable without any permanent modifications to the genome. These results demonstrate the feasibility of tunable transcriptional control in human cells.

4.4 Epigenetic Modification Patterns

Epigenetic analysis showed increased histone acetylation at activated loci and elevated DNA methylation at repressed targets. ChIP-qPCR analysis showed that dCas9-VP64 treatment resulted in enrichment of H3K27ac activation marks, while dCas9-KRAB led to accumulation of H3K9me3 repressive marks. ATAC-seq results showed dynamic changes in chromatin accessibility accompanying transcriptional modulation.

4.5 Off-Target Assessment

Analysis of genome-wide specificity showed low off-target effects of CRISPR/dCas9 systems, with nonspecific transcriptional effects below 5%. This optimized guide RNA design markedly improved targeting accuracy compared with previous epigenome editing methods. However, we observed small unintentional changes to chromatin in highly repetitive genomic regions.

4.6 Comparison and Evaluation

Comparative studies showed that CRISPR/dCas9 platforms exceeded TALE and ZFP systems in activation efficiency, targeting flexibility and reversibility . TALE-based systems showed high specificity but lower scalability due to the complex protein engineering requirements. ZFP platforms had advantages in compact delivery, but reduced targeting precision compared with CRISPR systems.



Figure 3. Relative Gene Expression Profiles

Figure 3 Comparison of gene expression levels after epigenome editing treatments. dCas9-VP64 and TALE activators robustly activated transcription of the activated genes OCT4 and NANOG, whereas dCas9-KRAB-mediated repression robustly decreased SOX2 expression. The graph demonstrates that the CRISPR/dCas9 systems achieved the highest transcriptional modulation with high reproducibility and specificity between biological replicates.



Figure 4. Reversible Regulation Timeline

Figure 4. Temporal changes in reversible gene regulation in human cells. Epigenome editing constructs led to rapid activation or repression of target genes within 48–72h of delivery. Over the next seven days, gradual removal of the constructs led to the restoration of endogenous transcriptional activity. This timeline shows that programmable epigenetic regulation can be induced and reversed repeatedly without permanent DNA modification, supporting its potential applications in precision medicine and therapeutic gene control.

4.7 DISCUSSION

The results demonstrate that engineered epigenome editing platforms allow efficient and reversible regulation of gene expression in human cells. CRISPR/dCas9 systems showed enhanced activation, repression and specificity compared to TALE and ZFP technologies. These findings emphasize the biological significance of programmable chromatin remodeling in therapeutic applications, disease modeling and synthetic biology. However, technical

challenges such as delivery efficiency, residual epigenetic memory, and low-level off-target effects remain hurdles for clinical translation. Future optimization strategies should include the development of better delivery systems, increased guide RNA specificity, and long-term safety validation in vivo.

5 CONCLUSIONS

In this study, we demonstrated that engineered epigenome editing platforms can be used for effective reversible regulation of gene expression in human cells without permanent changes to genomic DNA. The CRISPR/dCas9-based activator and repressor systems were more efficient, specific and programmable than TALE and ZFP platforms. Prominent activation of OCT4 and repression of SOX2 confirmed the capacity of programmable epigenetic modifiers to regulate transcriptional activity by reversible chromatin remodeling. Over time, studies also demonstrated that upon withdrawal of the editing constructs, the native gene expression was restored, underscoring the dynamic and tunable nature of epigenome engineering. However, off-target effects, delivery efficiency and epigenetic memory are challenges that are yet to be addressed. The findings support the potential of reversible epigenome editing in precision medicine, disease modelling, regenerative therapy and synthetic biology. Future research should focus on long term safety and clinical translation strategies for targeting accuracy.

REFERENCES

1. Bird A. Perceptions of epigenetics. *Nature*. 2009;447(7143):396–398.
2. Portela A, Esteller M. Epigenetic modifications and human disease. *Nat Biotechnol*. 2010;28(10):1057–1068.
3. Goldberg AD, Allis CD, Bernstein E. Epigenetics: a landscape takes shape. *Cell*. 2017;128(4):635–638.
4. Bannister AJ, Kouzarides T. Regulation of chromatin by histone modifications. *Cell Res*. 2011;21(3):381–395.
5. Hilton IB, et al. Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers. *Nat Biotechnol*. 2015;33(5):510–517.
6. Thakore PI, et al. Highly specific epigenome editing by CRISPR-Cas9 repressors for silencing distal regulatory elements. *Nat Methods*. 2015;12(12):1143–1149.
7. Kearns NA, et al. Functional annotation of native enhancers with a Cas9-histone demethylase fusion. *Nat Methods*. 2015;12(5):401–403.
8. Pulecio J, et al. CRISPR/Cas9-based engineering of the epigenome. *Cell Stem Cell*. 2017;21(4):431–447.
9. Doudna JA, Charpentier E. Genome editing: the new frontier of genome engineering with CRISPR-Cas9. *Science*. 2014;346(6213):1258096.
10. Zhang XH, et al. Off-target effects in CRISPR/Cas9-mediated genome engineering. *Mol Ther Nucleic Acids*. 2015;4:e264.
11. Nuñez JK, et al. Genome-wide programmable transcriptional memory by CRISPR-based epigenome editing. *Cell*. 2021;184(9):2503–2519.
12. O'Geen H, et al. Emerging strategies for programmable and reversible epigenome editing. *Trends Biotechnol*. 2024;42(2):145–160.
13. Cavalli G, Heard E. Advances in epigenetics link genome regulation to cellular function. *Nature*. 2022;611(7937):490–500.
14. Hyun K, et al. Writing, erasing and reading histone lysine methylations. *Nat Rev Mol Cell Biol*. 2022;23(10):643–661.
15. Statello L, et al. Gene regulation by long non-coding RNAs and RNA modifications. *Nat Rev Mol Cell Biol*. 2022;23(5):289–305.
16. Nuñez JK, et al. Programmable CRISPR-based epigenome editing for transcriptional regulation. *Cell*. 2023;186(4):765–781.
17. Amabile A, et al. Engineering programmable epigenetic modulators for human cell applications. *Trends Biotechnol*. 2023;41(8):1012–1025.
18. O'Geen H, et al. Reversible chromatin engineering using CRISPR-mediated epigenetic systems. *Nat Biotechnol*. 2024;42(3):310–322.
19. Li Y, et al. Emerging challenges and ethical considerations in therapeutic epigenome editing. *Genome Biol*. 2025;26(1):44–58.
20. Wang R, et al. Integrative epigenomic profiling using ATAC-seq and ChIP technologies in human cells. *Nat Methods*. 2026;23(1):55–67.